Zhang Dong-Mei, Huang Rong, Xiao Yi, Gong Feng-Ying, Zhong Xu, Luo Jin-Mei
Department of Respiratory Medicine, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Chin Med Sci J. 2017 Dec 30;32(4):211-217. doi: 10.24920/J1001-9294.2017.034.
Objective Obstructive sleep apnea (OSA) is closely related to obesity, insulin resistance and inflammation. Secreted frizzled-related protein 5 (SFRP5) is a recently discovered adipokine. It is involved in insulin resistance and inflammation in obesity. This study aimed at evaluating the association between SFRP5 and sleeping characteristics as well as biochemical parameters of OSA patients. Methods This was a prospective case control study. Nondiabetic OSA patients and controls were consecutively recruited and divided into three groups: OSA group, apnea-hypopnea Index (AHI)≥5/h; healthy controls with normal body mass index (BMI); obese controls without OSA, and BMI > 24.0 kg/m. All participants underwent polysomnography (PSG). Plasma SFRP5 was examined using enzyme-linked immunosorbent assay (ELISA). Blood biochemical examinations, including fasting blood glucose (FBG), lipid profile, hypersensitive C-reactive protein (hsCRP), were performed early in the morning after PSG. Patients with severe OSA were treated with nasal continuous positive airway pressure (nCPAP), and plasma SFRP5 was repeatedly measured for comparison. Results Sixty-eight subjects were enrolled in the study, including 38 patients of OSA, whose medium AHI was 58.70 /h (36.63, 71.15), 20 obese controls, and 10 healthy controls. The plasma SFRP5 level of OSA patients was not significantly different from that of healthy controls or obese controls. In OSA patients, SFRP5 level correlated positively with triglyceride level (r=0.447, P=0.005) and negatively with LDL-cholesterol level and HDL- cholesterol level (r=-0.472 and P=0.003; r=-0.478 and P=0.002; respectively). SFRP5 level was not found correlating with FBG, AHI, or any of nocturnal hypoxia parameters. After overnight nCPAP treatment, plasma SFRP5 levels of OSA patients did not change significantly (t=1.557, P = 0.148) compared to that of pretreatment. Conclusions In nondiabetic OSA patients, plasma SFRP5 is associated with the lipid profile. However, no correlation was observed between SFRP5 and FBG or sleep parameters. The SFRP5 level of OSA patients did not differ from that of non-OSA individuals in our study.
阻塞性睡眠呼吸暂停（OSA）与肥胖、胰岛素抵抗及炎症密切相关。分泌型卷曲相关蛋白5（SFRP5）是最近发现的一种脂肪因子，参与肥胖中的胰岛素抵抗和炎症过程。本研究旨在评估SFRP5与OSA患者睡眠特征及生化参数之间的关联。方法：这是一项前瞻性病例对照研究。连续招募非糖尿病OSA患者及对照，分为三组：OSA组，呼吸暂停低通气指数（AHI）≥5次/小时；体重指数（BMI）正常的健康对照；无OSA的肥胖对照，BMI>24.0kg/m²。所有参与者均接受多导睡眠图（PSG）检查。采用酶联免疫吸附测定（ELISA）检测血浆SFRP5。PSG检查后清晨进行血液生化检查，包括空腹血糖（FBG）、血脂、超敏C反应蛋白（hsCRP）。对重度OSA患者采用经鼻持续气道正压通气（nCPAP）治疗，并反复测量血浆SFRP5进行比较。结果：本研究共纳入68名受试者，其中OSA患者38例，平均AHI为58.70次/小时（36.63，71.15），肥胖对照20例，健康对照10例。OSA患者血浆SFRP5水平与健康对照或肥胖对照无显著差异。在OSA患者中，SFRP5水平与甘油三酯水平呈正相关（r = 0.447，P = 0.005），与低密度脂蛋白胆固醇水平和高密度脂蛋白胆固醇水平呈负相关（r = -0.472，P = 0.003；r = -0.478，P = 0.002）。未发现SFRP5水平与FBG、AHI或任何夜间缺氧参数相关。经夜间nCPAP治疗后，OSA患者血浆SFRP5水平与治疗前相比无显著变化（t = 1.557，P = 0.148）。结论：在非糖尿病OSA患者中，血浆SFRP5与血脂相关。然而，未观察到SFRP5与FBG或睡眠参数之间的相关性。在本研究中，OSA患者的SFRP5水平与非OSA个体无差异。
